Skip to content

Inspection Record

Unilab Chemicals and Pharmaceuticals Private Ltd. — FDA 483 Findings

US FDAInspected 2026-02-27Published 2026-10-22 5 findingsMaterial and supplier controlQuality unit oversightCleaning validationDeviation, CAPA, and investigationTraining and personnel

Inspectors Guerlain UlysseThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

There is a failure to establish the reliability of the component supplier's report of analyses.

2Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing or fully followed.

3Cleaning validation

There is a failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.

4Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy whether or not the API batch has already been distributed.

5Training and personnel

GMP training is not conducted with sufficient frequency to assure that employees remain familiar with cGMP requirements applicable to them.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Unilab Chemicals and Pharmaceuticals Private Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.